Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

583
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
583
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

312
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
312
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidental Detection of Respiratory Viruses in Lung Transplant Donor-Recipient Pairs: Exploratory Associations With Clinical Outcomes in a Post Hoc Analysis.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Performance of the BioFire FilmArray Pneumonia Panel Plus Compared to Standard Microbiology in Lung Transplant Donor and Recipient Samples: A Prospective Cohort Study.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Molecular Respiratory Pathogen Panels in Lung Transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2025
Same author

Vaccinations Included in the National Immunization Calendar as a Tool to Tackle Antimicrobial Resistance: Current Evidence for Selected Pathogens in Italy.

Vaccines·2025
Same author

Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study.

BMC infectious diseases·2025
Same author

Early Onset Mycoplasma spp. Infection After Kidney Transplantation: A Systematic Review.

Clinical transplantation·2025

Related Experiment Video

Updated: Feb 2, 2026

Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe
06:16

Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe

Published on: March 1, 2022

4.6K

Hepatitis C: Is eradication possible?

Andrea Lombardi1,2, Mario U Mondelli1,2,

  • 1Division of Infectious Diseases II and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Liver International : Official Journal of the International Association for the Study of the Liver
|November 26, 2018
PubMed
Summary

Hepatitis C eradication faces significant challenges, including low awareness and treatment barriers, hindering global elimination goals. Without an effective vaccine, achieving widespread Hepatitis C (HCV) elimination by 2030 remains difficult.

Keywords:
DAAHCVHCV-vaccinelinkage to careviral eradication

More Related Videos

Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Related Experiment Videos

Last Updated: Feb 2, 2026

Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe
06:16

Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe

Published on: March 1, 2022

4.6K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Area of Science:

  • Hepatology and Infectious Diseases
  • Global Public Health
  • Virology

Background:

  • Hepatitis C (HCV) affects over 70 million globally, causing significant morbidity, mortality, and economic burden.
  • The 2030 Agenda for Sustainable Development includes combating viral hepatitis as a key health goal.
  • The World Health Organization (WHO) Global Viral Hepatitis Strategy aims for an 80% treatment rate and a two-thirds reduction in deaths.

Purpose of the Study:

  • To assess the global impact of Hepatitis C and the feasibility of its eradication.
  • To identify barriers hindering the achievement of WHO's viral hepatitis elimination targets.
  • To evaluate the role of direct-acting antivirals and the need for prophylactic vaccines.

Main Methods:

  • Review of global Hepatitis C epidemiology and economic impact.
  • Analysis of the WHO Global Viral Hepatitis Strategy and its targets.
  • Identification and discussion of barriers to HCV treatment and eradication.

Main Results:

  • Despite effective direct-acting antiviral therapies, significant barriers impede HCV eradication.
  • Key challenges include lack of awareness, poor linkage to care, drug accessibility, and reinfection.
  • Current strategies may be insufficient to achieve elimination without a prophylactic vaccine.

Conclusions:

  • Hepatitis C eradication is a complex global health challenge requiring multifaceted interventions.
  • Addressing awareness, care access, and treatment availability is crucial for progress.
  • The development of an effective prophylactic vaccine is likely essential for future HCV elimination.